The HEBP2 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function studies of the heme-binding protein 2 (HEBP2) gene. Generated through CRISPR/Cas9-mediated gene disruption of HEBP2 in Jurkat T lymphoblasts, this product provides a heterogeneous pool of cells with targeted gene knockout, eliminating the need for single-cell cloning. The polyclonal format enables robust, reproducible population-level analyses of HEBP2-dependent cellular processes, particularly apoptosis and heme trafficking, in an experimentally accessible T-cell leukemia model.
Jurkat cells are an immortalized T lymphocyte line derived from a patient with acute T cell leukemia, widely utilized for investigating T-cell signaling, apoptosis, and leukemogenesis. These lymphoblasts retain many characteristics of their malignant origin, including expression of T-cell receptors and functional apoptotic machinery, making them a standard host for dissecting oncogenic pathways. Their acute T cell leukemia background provides a physiologically relevant context for studying how HEBP2 disruption affects heme metabolism and cell death regulation.
HEBP2 encodes a heme-binding protein that governs intracellular heme distribution and intersects with the intrinsic apoptosis pathway. Mechanistically, HEBP2 interacts directly with heme and is influenced by intracellular heme levels, oxidative stress, and NRF2-mediated transcription. It modulates cytochrome c release from mitochondria, acting upstream of caspase-9 (CASP9) and caspase-3 (CASP3) activation. Additionally, HEBP2 is linked to Bcl-2, mTOR, and p53, forming a network where heme availability, apoptotic signaling, and metabolic sensing converge. Knockout of HEBP2 disrupts heme binding, impairing heme-induced cytochrome c release and caspase cascade activation, while also altering reactive oxygen species production.
In the Jurkat host, HEBP2 knockout provides a targeted tool to dissect heme-dependent apoptotic regulation in a T-cell leukemia model. By ablating HEBP2, researchers can examine how defective heme trafficking perturbs mitochondrial integrity and caspase activation, revealing potential vulnerabilities in leukemia cell survival. This system is particularly informative for studying crosstalk between heme metabolism and redox signaling, as well as interactions with Bcl-2 family proteins, mTOR, and p53 under conditions that mimic the neuroinflammatory or oxidative stress environment of acute T cell leukemia.
Key research applications include assessing apoptosis sensitivity via Annexin V assays, quantifying cleaved caspases by Western blotting, measuring intracellular heme levels, monitoring mitochondrial membrane potential with JC-1 flow cytometry, and detecting reactive oxygen species using DCFDA. These cells enable functional screening for modulators of heme metabolism, investigation of redox signaling in T-cell leukemia, and mechanistic studies of HEBP2’s role in cytochrome c release and caspase activation. The polyclonal knockout design supports consistent, scalable experiments for target validation and pathway dissection. For further technical information or to discuss customized applications, please contact Ascent Research.
